198 related articles for article (PubMed ID: 20960523)
1. Screening, risk assessment, and the approach to therapy in patients with prostate cancer.
Freedland SJ
Cancer; 2011 Mar; 117(6):1123-35. PubMed ID: 20960523
[TBL] [Abstract][Full Text] [Related]
2. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
Simmons MN; Stephenson AJ; Klein EA
Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
4. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
6. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
7. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
9. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
11. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
12. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
13. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
14. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
15. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
16. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
17. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
19. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
20. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH
Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
